Soligenix Expands European Medical Advisory Board to Advance HyBryte Development for Cutaneous T-Cell Lymphoma

Soligenix Inc. has expanded its European Medical Advisory Board to provide additional clinical and strategic guidance as the company advances its confirmatory Phase 3 study evaluating the safety and efficacy of HyBryte for cutaneous T-cell lymphoma. The expansion underscores the company's commitment to delivering innovative treatment options to European patients suffering from this rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Cutaneous T-cell lymphoma presents a substantial unmet medical need, particularly in early-stage patients who often have limited treatment options available to them.

Globally, millions suffer from CTCL, with European annual incidence estimated at 2.9 to 3.9 cases per million people according to epidemiological data available at https://ibn.fm/ANk8X. Despite its rarity, the condition significantly impacts patients' quality of life and requires effective therapeutic interventions. HyBryte represents a first-in-class photodynamic therapy using synthetic hypericin as a photosensitizer, potentially establishing it as a new standard of care for patients who currently have limited treatment alternatives.

The company's strategic move to strengthen its European Medical Advisory Board, as detailed in their recent announcement at https://ibn.fm/6354Y, represents a crucial step in ensuring the successful execution of the FLASH2 study and navigating the complex regulatory and clinical landscape across European markets. This expansion comes at a critical juncture in the development pathway for HyBryte, as positive results from the Phase 3 trial could lead to regulatory submissions and eventual market approval in European countries.

The development of HyBryte addresses a significant gap in the treatment landscape for cutaneous T-cell lymphoma patients in Europe. Current treatment options for early-stage CTCL patients remain limited, often involving topical therapies that may provide inadequate symptom control or systemic treatments with substantial side effects. The photodynamic approach of HyBryte offers a potentially safer and more targeted therapeutic option that could improve patient outcomes while minimizing adverse effects commonly associated with existing treatments.

Soligenix's commitment to expanding its European medical expertise through the advisory board expansion demonstrates the company's strategic focus on ensuring that HyBryte meets the specific needs of European patients and healthcare systems. The enhanced advisory board will provide valuable insights into regional treatment practices, patient care standards, and regulatory requirements that are essential for the successful development and potential commercialization of HyBryte across European markets.